Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
---|
03/31/2004 | EP1402262A2 MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE |
03/31/2004 | EP1402260A2 Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders |
03/31/2004 | EP1402256A2 P-cadherin as a target for anti-cancer therapy |
03/31/2004 | EP1402075A1 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
03/31/2004 | EP1402067A2 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE |
03/31/2004 | EP1402066A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
03/31/2004 | EP1402064A2 Protein arrays and methods and systems for producing the same |
03/31/2004 | EP1402058A2 Dgks as modifiers of the p53 pathway and methods of use |
03/31/2004 | EP1402054A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
03/31/2004 | EP1402053A2 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
03/31/2004 | EP1402051A2 Lces as modifiers of the p53 pathway and methods of use |
03/31/2004 | EP1402039A1 MUTANT FORMS OF EtxB AND CtxB AND THEIR USE AS CARRIERS |
03/31/2004 | EP1402031A2 Atopy |
03/31/2004 | EP1402030A2 43238, a g protein-coupled receptor and uses therefor |
03/31/2004 | EP1402019A1 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes |
03/31/2004 | EP1402015A2 A soluble complex comprising a retroviral surface glycoprotein |
03/31/2004 | EP1402000A2 Structural and cytoskeleton-associated proteins |
03/31/2004 | EP1401918A2 Biodegradable poly(beta-amino esters) and uses thereof |
03/31/2004 | EP1401872A1 Antigen targeting |
03/31/2004 | EP1401871A1 Immunological binding molecules inhibiting the syncytial fusion of trophoblast cells |
03/31/2004 | EP1401870A2 Antibodies against tumor necrosis factor delta (april) |
03/31/2004 | EP1401869A1 Molecules and methods for inhibiting shedding of kim-1 |
03/31/2004 | EP1401867A2 Mycobacterial antigens expressed under low oxygen tension |
03/31/2004 | EP1401866A2 Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses |
03/31/2004 | EP1401865A2 Pathogenic and commensal vaccine antigens |
03/31/2004 | EP1401861A2 Cads as modifiers of the p53 pathway and methods of use |
03/31/2004 | EP1401859A2 Chimeric flavivirus vectors |
03/31/2004 | EP1401858A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
03/31/2004 | EP1401855A2 Novel fibroblast growth factor and nucleic acids encoding same |
03/31/2004 | EP1401849A1 Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes |
03/31/2004 | EP1401498A1 Anti-ngf antibodies for the treatment of various disorders |
03/31/2004 | EP1401496A1 Compositions and methods for treating hyperimmune response in the eye |
03/31/2004 | EP1401493A1 Subunit vaccines and processes for the production thereof |
03/31/2004 | EP1401492A1 Ltb4 as vaccine adjuvant |
03/31/2004 | EP1401491A1 Methods for inducing an immune response with an elevated th1/th2 ratio, by intracellular induction of nfkappab |
03/31/2004 | EP1401489A2 Capsular polysaccharide solubilisation and combination vaccines |
03/31/2004 | EP1401488A1 Mycoplasma bovis vaccine and methods of reducing pneumonia in animals |
03/31/2004 | EP1401486A2 Novel human proteins, polynucleotides encoding them and methods of using the same |
03/31/2004 | EP1401479A2 Detection and therapy of vulnerable plaque with photodynamic compounds |
03/31/2004 | EP1401476A2 Igf antagonist peptides |
03/31/2004 | EP1401475A2 Prmts as modifiers of the p53 pathway and methods of use |
03/31/2004 | EP1401472A2 Alternative splice forms of proteins as basis for multiple therapeutic modalities |
03/31/2004 | EP1401470A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
03/31/2004 | EP1401443A1 Novel anti-infectives |
03/31/2004 | EP1401410A2 Immunomodulation and effect on cell processes relating to serotonin family receptors |
03/31/2004 | EP1401377A2 Methods for treating cancer |
03/31/2004 | EP1401281A2 Toll/interleukin-1 receptor adaptor protein (tirap) |
03/31/2004 | EP1401269A2 Transgenic animal model of bone mass modulation |
03/31/2004 | EP1181318B1 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules |
03/31/2004 | EP1015560B1 Modified small rna viruses |
03/31/2004 | EP0877624B1 Streptococcal c5a peptidase vaccine |
03/31/2004 | EP0858343B1 Continuous low-dose cytokine infusion therapy |
03/31/2004 | EP0784677B1 Inhibitor of stem cell proliferation and uses thereof |
03/31/2004 | EP0656948B1 Bordetella bronchiseptica vaccine |
03/31/2004 | CN1486206A Methods and vaccines for providing in ovo protection against turkey rhinotracheitis |
03/31/2004 | CN1486194A Colorstrum-based composition |
03/31/2004 | CN1486192A Binding domain-immunoglobulin fusion proteins |
03/31/2004 | CN1486191A Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
03/31/2004 | CN1485343A Production method of specific IgY for venereal disease and its combined preparation |
03/31/2004 | CN1485095A Preparation process of the freeze drying protective agent for the vaccin used for animals |
03/31/2004 | CN1484972A Anti-diarrhea yelk antibody feed additive for swine and injection formulation, and preparation method |
03/31/2004 | CN1143679C Method and material for treating and preventing mucosal tissue inflammation |
03/30/2004 | US6713617 Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens |
03/30/2004 | US6713450 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid β for induction of an immune response to amyloid β and amyloid deposits |
03/30/2004 | US6713301 Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens |
03/30/2004 | US6713296 Due to a deletion of at least 10 amino acids, neurovirulence is attenuated as compared to a naturally occurring varicella-zoster virus |
03/30/2004 | US6713291 Method of immunotherapy; obtain electrodes, obtain waveform generator, generate electrically conductive pathways between electrodes and generator, incubate with transfer particles, transfer particles into cells with electrical pulse |
03/30/2004 | US6713286 Purified fiv-141 virus; vaccines |
03/30/2004 | US6713282 End selection in directed evolution |
03/30/2004 | US6713279 Targeting of a genetic vaccine to a particular tissue or cell type of interest by creating a library of mutant polypeptides and screening them against cell of interest |
03/30/2004 | US6713266 Immunoassay method for measuring a cyclosporine and its metabolites |
03/30/2004 | US6713073 Whole body spray |
03/30/2004 | US6713072 Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine |
03/30/2004 | US6713071 Proteins from actinobacillus pleuropneumoniae |
03/30/2004 | US6713069 Compositions and methods for detecting, preventing, and treating African Hemorrhagic Fever |
03/30/2004 | US6713068 Live recombined vaccines injected with adjuvant |
03/30/2004 | US6713066 Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2 |
03/30/2004 | US6713064 Immune enhancing agent for treating HIV infected humans |
03/30/2004 | US6713059 Antibodies raised against immunogenic conjugates of gram-negative bacterial autoinducer molecules |
03/30/2004 | US6713056 Combined preparation for the treatment of neoplasic diseases or of infectious diseases |
03/30/2004 | CA2277165C Purification and/or concentration of dna by cross-flow filtration, separation of endotoxins from a nucleic acid preparation |
03/30/2004 | CA2235471C Dna encoding a plasminogen activating protein |
03/30/2004 | CA2136103C Antibiotic cryptdin peptides and methods of their use |
03/25/2004 | WO2004025416A2 Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby |
03/25/2004 | WO2004025267A2 Method for testing drug susceptibility of hiv |
03/25/2004 | WO2004025263A2 Protein and peptide expression for passive immunity |
03/25/2004 | WO2004025256A2 Viral deconstruction through capsid assembly in vitro |
03/25/2004 | WO2004024952A1 Method of diagnosing ovarian endometriosis |
03/25/2004 | WO2004024937A2 Virulence-associated nucleic acids and proteins and uses thereof |
03/25/2004 | WO2004024920A1 Preventives/remedies for neurodegenerative diseases |
03/25/2004 | WO2004024909A2 Recombinant colstridium neurotoxin fragments |
03/25/2004 | WO2004024904A2 Infectious hepacivirus pseudo-particles containing functional e1, e2 envelope proteins |
03/25/2004 | WO2004024902A1 A method of treating an autoimmune disease |
03/25/2004 | WO2004024900A1 USE OF DENDRITIC CELLS (DCs) EXPRESSING INTERLEUKIN 12 (IL-12) |
03/25/2004 | WO2004024889A2 Production of bispecific molecules using polyethylene glycol linkers |
03/25/2004 | WO2004024884A2 Syts as modifiers of the p21 pathway and methods of use |
03/25/2004 | WO2004024883A2 PAKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE |
03/25/2004 | WO2004024882A2 FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
03/25/2004 | WO2004024880A2 AMPDs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
03/25/2004 | WO2004024879A2 RORs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |